#Lundbeck #phase3 #migraineprevention #migrainepreventiondrug #bocunebart #antiPACAPantibody #phase2b #PROCEEDtrial #intravenousbocunebart #LuAG09222 #monthlymigrainedays #MMD #PACAP #neuropeptide #pathophysiologyofmigraine #migrainetreatment #PACAPpathway #migrainepreventionmarket
zurl.co/M7FHE
zurl.co/M7FHE
Lundbeck preps phase 3 for migraine prevention drug
Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.
pharmaphorum.com
February 13, 2026 at 12:53 PM